Black vs White Race Tied to Worse Survival in Renal Cell Carcinoma
While socioeconomic disparities are evident, survival differences between racial groups persist after RCC diagnosis.
Renal Cell Carcinoma
ICIs May Improve mRCC Outcomes in Cytoreductive Nephrectomy Cases
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
HRQOL Data Support First-Line Lenvatinib-Pembrolizumab in Advanced Renal Cell Carcinoma
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
DNA Assay May Distinguish Responses to mRCC Immunotherapy
The TARDIS assay could be used to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
Efficacy, Safety of Triple Combo for Advanced Kidney Cancer Probed
Study provides preliminary data on triple therapy for advanced RCC while clinicians await definitive answers from the ongoing phase 3 COSMIC-313 trial.
Treatment Advances Have Upped Survival in Metastatic Kidney Cancer
Investigators in Austria studied overall survival in 914 patients diagnosed with mRCC from July 1985 to September 2020.
COVID-19 mRNA Vaccine Efficacy Wanes Over Time in RCC Cases
Strategies such as booster doses appear warranted in this population.
Kidney Cancer Metastases Effectively Treated With Robotic Radiosurgery
Investigators examined outcomes of robotic radiosurgery in patients with lung, visceral, and lymph node metastases from renal cell carcinoma.
Lenvatinib+Pembrolizumab Adverse Reactions in Advanced RCC Characterized
Investigators describe the type and frequency of adverse reactions and how clinicians managed them.
Frontline Immunotherapy Appears Effective in mRCC With Poor Performance Status
Patients with poor performance status have been excluded from pivotal trials on metastatic renal cell carcinoma.
- Loading...
Loading...
Next post in Renal Cell Carcinoma
Loading... 
Loading...